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ABSTRACT 
Decarbonylation of Mo and W hexacarbonyls in the presence of dimethylglyoxime was carried out under the 
control of trimethylamine N-oxide (TMNO). The two DMG substituted carbonyl complexes were prepared in a 
one pot synthesis using manipulated Schlenk techniques under dinitrogen in tetrahydrofuran. The Mo complex 
system was successfully carried out by stirring the mixture of the molybdenum hexacarbonyl and DMG in 
tetrahydrofuran at room temperature for 18hrs. A similar procedure afforded the starting ligand material for the 
W complex analogue. However, further refluxing for 6 h gave the desired W complex. The complexes were 
characterized using 1H NMR, IR, and CHN analyses. Results showed that the reactions produced analytically 
pure, mono-product dicarbonyl species; Mo(CO)2(DMG)2 I and W(CO)2(DMG)2 II where two DMG moieties 
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INTRODUCTION 
Metal ions and metal containing compounds 
are believed to be toxic in vivo because of their 
perceived interaction with biological substances, 
hence organometallic compounds are rarely 
considered as pharmaceutical agents (Gasser and 
Metzler-Nolte, 2012). Generally, the development 
of metallodrugs have for a long time been 
hampered by their perceived undesired interactions 
with DNA and other biomolecules (Gasser and 
Metzler-Nolte, 2012). However, the discovery of 
the cancer drug, Cisplatin changed the fate of 
classical coordination compounds but 
bioorganometallic molecules continue to suffer 
more due to the paradigm that ‘organometallics are 
unstable in air and water’ (Hartinger & Dyson, 
2009). 
Recent research findings, in several reviews; 
have dealt comprehensively with founding 
principles  and exciting medicinal applications 
(Jaouen, 2006, Jaouen and Salmain, 2015, Jaouen 
and Metzler-Nolte, 2010), challenges and prospects 
in exploring organometallics as drug candidate 
(Jaouen and Dyson, 2007, Metzler-Nolte, 2007) as 
well as their roles in several novel pharmaceutical 
screenings (Simonneaux, 2006, Fish and Jaouen, 
2003). All of which have shown that certain 
bioorganometallic compounds are stable in air and 
water and in some cases metals as well as their 
particular complexes have a diversity of chemical 
properties and hence ‘the notion that they should 
all come down to one and the same cellular target; 
DNA seems most unlikely and organometallic 
compounds do play vital roles in drug design and 
discovery (Gasser and Metzler-Nolte, 2012). 
Preceding the period of the teaching 
paradigms that organometallics are unstable in air 
and water, they have played vital roles in biology. 
Some organometallic compounds existed naturally 
as biomolecules, these include the cobalamines; 
vitamin B12 and its derivatives (Gibaud and Jaouen, 
2010), the hydrogenase family (McGlynn, et al., 
2009) which catalyzes the useful process of the 
reversible conversion of dihydrogen into protons 
and electrons in biological system. 
Despite the issue of toxicity some 
organometallics were used as drugs, the most 
popular being Paul Ehrlich’s Salversan and its 
analogue, Neo-Salversan. They were the only 
remedy for syphilis at a time when syphilis ravaged 
like AIDS did at the present time (Gibaud and 
Jaouen, 2010). For a very long time melasoprol, 
another organometallic drug remained the first-line 
treatment for patients with Trypanosoma brucei 
gambiense trypanosomiasis and is still used in 
African countries even though it is toxic and 
treatment result in the development of an extremely 
severe reactive arsenic encephalopathy (RAE). The 
reality is; in the face of this unacceptable toxicity 
melasoprol will be in use as it is unlikely that any 
new drug will replace it anytime soon (Gasser and 
Metzler-Nolte, 2012, Gibaud and Jaouen, 2010) 
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One particular class of organometallics that 
have caught the fancy of the Bioorganometallic 
Chemist is transition metal carbonyls. 
Appropriately substituted metal carbonyls have 
been recognized as a potential drug candidate due 
to its ability to slowly and systematically release 
carbon monoxide (CO) molecule in biological 
system, making it arguably the best class of the so 
called CO-releasing molecules (CO-RMs) (Romao, 
et al., 2012) 
There is Preclinical evidence that CO 
administration in animals have beneficial effects in 
cardiovascular diseases, sepsis, shock, cancer, 
acute lung, liver and kidney injury and etcetera 
(Nakatsu, et al, 2002, Abraham, et al, 2002, Wang, 
2004). The technology for production and delivery 
(for inhalation) of pharmaceutical grade CO is 
quite limited at the moment and only available in 
highly specialized hospitals. CO ingestion is 
obviously challenging and can be carried out as pro 
drug and as CO-releasing molecules (CO-RMs), 
with CO-RMs being the most effective. Five 
classes of CO-RMs have been identified and of 
these, appropriately substituted transition metal 
carbonyls stand out as the most effective means of 
safe CO delivery to specific sites in biological 
systems (Romao, et al., 2012). 
For a full medicinal exploitation of this class 
of compounds a detailed understanding of their 
structural chemistry is required. Here we set out to 
synthesize and characterise two DMG substituted 
Mo and W carbonyl complexes. 
 
MATERIALS AND METHOD 
Materials 
Molybdenum and tungsten hexacarbonyls, 
trimethylamine N-oxide dehydrate (TMNO), 
dimethylglyoxime (DMG) and tetrahydrofuran 
(THF) were purchased from Sigma Aldrich. 
Tetrahydrofuran (THF) was purified prior to 
use according to the method described in literature 
(Armarego and Chai, 2003). All other solvents 
were AR grade from Sigma Aldrich and were used 
without further purification. 
  
METHODS 
All reactions involving metal carbonyls 
were performed under pure dry nitrogen gas using 
manipulated Schlenk techniques. Solvents were of 
reagent grade and purified according to standard 
methods. Infrared spectra were obtained using 
SHIMADZU Fourier transform infrared 
spectrometer using KBr disc pellets technique. 1H 
NMR and Microanalysis were performed by Medac 
analytical and chemical consultancy services, UK, 
using Bruker Avance III HD 500 spectrometer and 
Thermo Flash 1112 elemental analyser 
respectively. 
 
Purification of Tetrahydrofuran 
The tetrahydrofuran (THF) tested negative 
for peroxide when tested with cobalt chloride 
paper. The solvent was however passed through a 
column of activated silica gel. The silica gel was 
predried in an oven at 100o C for 24 hours and 
thereafter allowed to cool to room temperature in a 
desiccator before use. The solvent was then dried 
by passing it over a column of the desiccant inside 
the glove box (Armarego and Chai, 2003). 
 
PREPARATION OF SUBSTITUTED 
COMPLEXES  
Preparation of [Mo(CO)2(DMG)2] (I) 
The preparation of the complexes by 
decarbonylation of metal hexacarbonyls using 
TMNO as decarbonylating agent follow the method 
described in literature (Hor and Siti, 1988) with 
minor  modifications 
In a one pot synthesis, TMNO.2H2O (0.339 
g, 3.06 mmol), Mo(CO)6 (0.792 g, 3.0 mmol), and 
DMG (0.348 g, 3.0 mmol) were weighed and 
dissolved in 20 mL THF in a flask equipped with a 
magnetic stirrer. The mixture was vigorously 
stirred under N2. An initial light yellow solution 
changed to a red suspension after a few minutes. 
The stirring was continued for 24 hours at room 
temperature. The mixture was then reduced to very 
low volume immediately with rotary evaporator, 
washed with minimal quantity of CH2Cl2/n-hexane 
(1:1) and left to crystallize. The brown crystals 
were washed with CH2Cl2/n-hexane under suction 
(Hor and Siti, 1988). (Yield 56%) 
 
Preparation of [W(CO)2(DMG)2] (II) 
TMNO.2H2O (0.339 g, 3.06 mmol), 
W(CO)6 (1.056 g, 3.0 mmol), and DMG (0,348 g, 
3.0 mmol) were weighed and dissolved in 20 mL 
THF in a flask equipped with a magnetic stirrer. 
The mixture was vigorously stirred under N2. An 
initial light yellow solution changed to a red 
suspension after a few minutes. The stirring was 
continued for 24 hours at room temperature and 
further refluxed for six hours. The mixture was 
then reduced to low volume immediately with 
rotary evaporator, washed with minimal quantity of 
CH2Cl2/n-hexane (1:1) the mixture which turned 
yellow was left to crystallize. The yellow crystals 
(Yield 63%) were washed with CH2Cl2/n-hexane 
under suction (Hor and Siti, 1988). 
 
RESULTS AND DISCUSSION 
The DMG Substituted Carbonyl 
Complexes 
The reactions of molybdenum and tungsten 
hexacarbonyl with dimethylglyoxime under 
nitrogen atmosphere in the presence of 
trimethylamine N-oxide yielded the dicarbonyl 
complexes as illustrated in scheme 1. 












Scheme 1: Route to the dimethylglyoxime stabilization of the TMANO decarbonylation of metal hexacarbonyl
M = Mo, W
 
The FTIR and elemental analysis result of the 
complexes are presented in Tables 1 and 2 The 
dimethylglyoxime was subjected to both infrared 
and CHN analysis before use, the results were 
positive. 
The FTIR spectra of the free DMG ligand shows 
stretching frequencies that are due to OH, NH and 
NO bands as shown in Table 2. A remarkable 
feature of the oximato group is the splitting of the 
NO stretching vibrations at 1440 cm-1 and 1365 cm-
1 in both complexes. Complexes I and II display 
three peaks each at 2002 cm-1, 1921 cm-1, 1820 cm-
1 and 1998 cm-1, 1934 cm-1, 1892 cm-1 respectively. 
These bands are unambiguously assigned to 
terminal CO stretching vibrations. 
The three bands may not necessarily connote the 
presence of three carbonyl ligands, the weak bands 
at 1840 cm-1 and 1892 cm-1 in both complexes can 
be ascribed to coupling of CO ligands in trans 
positions which is common with octahedral 
dicarbonyl complexes. The three peaks are usually 
due to one symmetric and two asymmetric CO 
vibrations (Socrates, 2001). The suggestion that the 
complexes are likely to be dicarbonyls is further 
established by the microelemental analysis results. 
 
Table 1: Elemental analysis data for the dimethylglyoxime complexes 
Compounds %C %H %N 
Calc Found Calc Found Calc Found 
DMG 41.34 40.71 6.94 6.80 24.12 22.89 
I 31.24 31.33 4.20 5.17 14.59 15.00 
II 25.42 24.93 3.39 3.20 11.86 12.13 
 
Table 2: IR data for the ligand and metal DMG complexes in cm-1 
Compounds νNH νOH νCO νCN νN-O νM-O νM-N 
DMG 3207  3340  1653 1440/1365   
I 3213  3462 2002 
1921 
1840 
1637 1440/1365 586 468 
II 3302  3454 1998 
1934 
1892 
1647 1440/1365 596 426 
 
The mode of chelation of the DMG complex to the 
metal centers can be instructive from the FTIR 
results. Chelation of DMG to metal centers usually 
occur through the N atoms of the oxime moieties 
but recently cases of chelation via N of one oxime 
moiety and the O of the other in the same molecule 
have been reported. The FTIR chart of the 
substituted molybdenum carbonyl complex 
exhibited a very strong and prominent peak at 586 
cm-1 which is absent in both the free DMG and the 
molybdenum hexacarbonyl complex. This peak has 
been ascribed to Mo-O vibration thereby 
suggesting the involvement of at least one O atom 
in the oxime moiety in the coordination process. A 
similar band appearing very weak in the tungsten 
complex at 596 cm-1 may also be due to W-O. The 
new peaks at 426 cm-1 and 468 cm1 in complexes I 
and II are assigned to M-N coordination therefore 
leading to the proposed structures. 





































I                                                                             II
Fig 1: the proposed structure of the substituted complexes, Mo(CO)2(DMG)2 I and W(CO)2(DMG)2 II
 
In the 1H NMR spectra, the resonance around 2.6 in 
the two complexes are assigned to the 6 H of the 
two equivalent allylic CH3 groups on the 
dimethylglyoxime ligand, the singlets at 3.4 and 
11.3 are assigned to the proton of NH and OH 
respectively which are consistent with NH of aryl 
amines and OH of oxime. 
 
CONCLUSION 
The successful decarbonylation of 
molybdenum and tungsten hexacarbonyls in the 
presence of DMG promoted by trimethylamine N-
oxide is novel. Previous attempts via thermal and 
photolytic pathways (Ramadan, et al., 1997, 
Ramadan, 1998) in addition to the desired product 
gave some undesired products and hence the 
cumbersome process of product separation and 
purification. In this method the products were 
definite and analytically pure not requiring rigorous 
separation and purification processes.  
The resulting complexes with two CO 
ligands of decreased bond strength promises to be 
good candidates for CO release studies in 
biological system with the use of appropriate CO 
release activating agent, thus offering some hope 
for their use as CO-releasing molecules. The 
possible generation of a small CO molecule and 
other biocompatible substrates by these compounds 
serves as encouragement for future studies using 
fragment based drug approach in screening these 
molecules as Pharmaceutical agents. 
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